Naloxone Access: Answering Questions
Virtual Public Meeting
Tuesday, March 29, 2022
12:30 – 3 PM Eastern Time
Drug overdose persists as a major public health issue in the United States, killing 100,000 people from May 2020-April 2021. That’s the highest recorded number of overdose deaths in a 12-month period in the US according to the CDC. Synthetic opioids, such as fentanyl, were the primary driver of the increase in overdose deaths.
The Reagan-Udall Foundation for the FDA, in collaboration with the U.S. Food and Drug Administration, hosted a virtual public meeting to explore some of the most frequently asked questions about access to naloxone, a drug used to reverse opioid overdoses. Harm reduction specialists, physicians, pharmacists, and regulators shared their experiences in addressing the availability of this life-saving medication for heroin, fentanyl, and prescription opioid overdose.
Watch the full event below.
Moderated by Susan C. Winckler, RPh, Esq., Reagan-Udall Foundation for the FDA
|12:35 pm||Opening Remarks
Patrizia Cavazzoni, MD, U.S. Food and Drug Administration
Current Landscape of Naloxone Access
|2 pm||Public Comment
Members of the public may register ahead of time to provide two minutes of oral comments. (Limited to 30 speakers)